Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Takeaways and Considerations for the Future in the Treatment of SCLC

July 5th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the possibility of expanding the use of supportive care regimens to reduce the effects of myelosuppression in patients with SCLC.

Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases

July 3rd 2023

A panel of expert oncologists present the case of a 68-year-old man with newly diagnosed, extensive stage small-cell lung cancer and brain metastases, who is treated with carboplatin, etoposide, and durvalumab, and provide their initial impressions.

Evolving Role of Biomarkers in SCLC

July 3rd 2023

Faculty discuss the evolving role of molecular markers in small-cell lung cancer and the need for future research to identify improved biomarkers for targeted treatment options.

ONC-392/BNT316 Elicits Clinical Activity in Checkpoint Inhibitor–Resistant NSCLC

July 2nd 2023

ONC-392/BNT316 demonstrated early signs of antitumor activity and manageable safety in patients with metastatic, PD-(L)1–resistant non–small cell lung cancer.

Dr Saltos on Pembrolizumab Plus Vorinostat in mNSCLC

June 30th 2023

Andreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.

Dr Sun on the Association of Duration of Immunotherapy and OS in NSCLC

June 30th 2023

Lova L. Sun, MD, MSCE, discusses the association between duration of immunotherapy and overall survival in patients with advanced non–small-cell lung cancer.

Dr Spira on the Ongoing PACIFIC-8 Trial in Unresectable Stage III NSCLC

June 30th 2023

Alexander I. Spira, MD, PhD, FACP, discusses the ongoing phase 3 PACIFIC-8 trial of durvalumab in combination with domvanalimab following concurrent chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer.

Evolving Field of Molecular Testing in Non–Small Cell Lung Cancer

June 30th 2023

Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.

Dr Yang on the Results of the KEYNOTE-789 Trial in EGFR-mutant NSCLC

June 29th 2023

James Chih-Hsin Yang, MD, discusses the investigation of pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous non–small cell lung cancer.

Dr Pellini on the Use of ctDNA Monitoring After Chemoimmunotherapy Induction in NSCLC

June 29th 2023

Bruna Pellini, MD, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced non–small cell lung cancer treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel.

Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

June 29th 2023

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

June 29th 2023

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

Neoadjuvant Nivolumab/Chemo Wins EU Approval for Resectable PD-L1+ NSCLC

June 29th 2023

The European Commission has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer at high risk of recurrence with tumor cell PD-L1 expression of at least 1%.

Dr Lam on the Tumor Microenvironment in ALK Fusion+ Lung Cancer

June 29th 2023

Vincent K. Lam, MD, discusses findings from a study profiling the tumor immune microenvironment in patients with ALK fusion–positive lung cancer and potential future directions for this research.

FDA Grants Fast Track Status to Quaratusugene Ozeplasmid Plus Atezolizumab in ES-SCLC

June 29th 2023

The FDA has granted fast track designation to the combination of quaratusugene ozeplasmid and atezolizumab as maintenance therapy in patients with extensive-stage small cell lung cancer whose disease did not progress after receiving initial standard treatment with atezolizumab and chemotherapy.

Repotrectinib NDA Under NMPA Review for Locally Advanced or Metastatic ROS1+ NSCLC

June 28th 2023

The National Medical Products Administration in China has accepted for review a new drug application seeking the approval of repotrectinib for use in adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Galinpepimut-S Plus Nivolumab Provides Survival Benefits With Acceptable Safety in Mesothelioma

June 28th 2023

The combination of galinpepimut-S and nivolumab provided positive survival outcomes with an acceptable safety profile in patients with malignant pleural mesothelioma who were refractory to or relapsed after at least 1 line of standard treatment.

Practical Considerations Regarding the Incorporation of Supportive Care Into Practice

June 28th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, consider the broader impact of supportive care on cost burden and quality of life and share scenarios in which supportive care is most appropriate.

Quality of Life and Patient-Reported Outcome Measures in SCLC Treatment

June 28th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, share insights about the value of patient-reported outcomes studies and the extent to which they can shape treatment decisions.

Dr Murray on the Investigation of Prognostic Markers in Cemiplimab-treated NSCLC

June 27th 2023

Joseph Christopher Murray, MD, PhD, discusses the investigation of peripheral myeloid cells as prognostic markers in patients with non–small cell lung cancer treated with cemiplimab.